hrp0095p1-292 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Management and outcomes of congenital hyperinsulinism in infants and young children: a 5-year-experience from the tertiary referral hospital in Indonesia

Fadiana Ghaisani , Soesanti Frida , B Pulungan Aman , Tridjaja Bambang , RL Batubara Jose

Background: Congenital hyperinsulinism (CHI) is a rare condition that becomes the most frequent cause of severe and persistent hypoglycemia in infants and young children. It may lead to debilitating morbidity and mortality if being diagnosed lately. Congenital hyperinsulinism can be caused by monogenic or syndromic disorders. The prevalence of CHI in Indonesia is still unknown. However, the increasing number of cases referred to the tertiary hospital recently ...

hrp0082p1-d1-179 | Perinatal and Neonatal Endocrinology | ESPE2014

Variations in Protein Expression in Small-For-Gestational-Age Newborns

Ruiz-Gonzalez Maria Dolores , Canete Maria Dolores , Gomez-Chaparro Jose Luis , Lopez-Barea Juan Luis , Canete Ramon

Introduction: Small-for-gestionational-age newborns (SGA-NB) may present subsequent comorbidities affecting their metabolism, growth, and development. Analysis of changes in serum proteome profile expression in SGA-NB may provide physiopathological information and help to identify postnatal biomarkers.Aim: To compare serum proteome profiles in SGA vs AGA newborns, stratified by gestational age.Study population and method: The study...

hrp0084p1-107 | Perinatal | ESPE2015

Changes in Serum Protein Expression in Small-for-Gestational-Age Newborn Infants at Different Gestational Ages

Canete Ramon , Ruiz-Gonzalez Maria Dolores , Canete Maria Dolores , Gomez-Chaparro Jose Luis , Abril-Diaz Nieves , Lopez-Barea Juan Luis

Background: Small-for-gestational-age (SGA) newborn infants (NB) may present long-term comorbidities influencing their metabolism, growth and/or development. Although their serum proteome is unknown, altered expression of the proteome profile may provide information on their physiopathology and lead to the discovery of biomarkers for postnatal complications.Aim: To detect changes in the serum proteome in SGA-NB vs adequate-for-gestational-age (AGA) newbo...

hrp0089p3-p347 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P3 | ESPE2018

Genital Swelling and Ovarian Stimulation Syndrome in an Extremely Preterm Infant

Cristina Azcona Maria , Ochotorena Amaia , Prados Monica , Luis Leon Jose , Alzina Valentin

Introduction: Ovarian stimulation syndrome (OSS) in an infrequent disorder, in preterm infants under 30 weeks gestation. The are very few cases described in the literature. The immaturity, lack of gonadal axis feed-back or mutations in the FSH receptor genes, may explain its physiopathology. We present the case of a 26-week neonate with this syndrome.Case summary: 26-week newborn with extremely low weight (460g) born by emergency cesarean section due to ...

hrp0089p3-p383 | Thyroid P3 | ESPE2018

Corticosteroid Resistant Immune Thrombocytopenic Purpura, is it a Marker of Future Graves Disease?

Azcona Maria Cristina , Leon Jose Luis , Prados Monica , Ochotorena Amaia , Oliver Asier

Introduction: The Immune Thrombocytopenic Purpura (ITP) and Graves Disease (GD) have in common an autoinmune physiopathology. ITP is characterized by a platelet count less than 100 × 106/l in the absence of other cause. On one hand, ITP has been associated with thyroid dysfunction, without developing GD. On the other hand, GD might develop with moderate thrombocytopenia, generally more than 100×109/l. It is described that in most cases ITP might...

hrp0086p2-p285 | Diabetes P2 | ESPE2016

Permanent Neonatal Diabetes by Gene Mutation KCNJ11. Evolution and Treatment after Three Years with Sulphonylureas

Angeles Santos Mata Maria , Fernandez Viseras Irene , Torres Barea Isabel , Jose Macias Lopez Francisco , Catano Luis

Background: Permanent neonatal diabetes (PND)with heterozygous mutations of KCNJ11, respond to treatment with sulphonylureas. We report a case of PND in a baby, and mother previously mis-diagnosed with Type 1 DM. Both were switched from insulin to oral sulphonylureas. We evaluate the response and evolution.Case report: A male newborn at 37 weeks’ gestation, with a birthweight 2750 g (40thC) and length 48 cm (40thC), was admitte...

hrp0097p1-222 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Height evaluation in a group of patients with Prader Willi syndrome after 3 years of treatment with growth hormone

Lara Emma , Castel Molineli Ana , Pintado Mónica , Luis Ruibal Jose

Introduction: Prader–Willi syndrome (PWS) is a genetic disorder caused by the lack of expression of genes on the paternally inherited chromosome 15q11.2-q13 region. Clinical picture of PWS changes across life stages. PWS is characterized by endocrine abnormalities, such as growth hormone (GH) deficiency, obesity, central adrenal insufficiency, hypothyroidism, hypogonadism, and complex behavioural and intellectual difficulties. The recombinant human growt...

hrp0089p3-p204 | GH & IGFs P3 | ESPE2018

Children Born Small for Gestational Age Treated with Growth Hormone: Evolutionary Aspects

Vazquez Veronica Maria Padin , Costa David Albino Gomez , Garcia Aida Del Campo , Cordo Lourdes Rey , Martin Jose Luis Chamorro , Lorenzo Jose Ramon Fernandez

Introduction: Short stature is defined as stature less than −2 standars deviations (SD) for a person’s age and sex of the reference population. Short for gestational age children (SGA) represent 20% of all children with short stature. 10% of these can not catch-up and remains their height below −2 SD. Growth hormone (GH) treatment is a recognized therapy for SGA children authorized in Europe at 4 years old. There are studies that support that younger children ...

hrp0082p2-d3-360 | Diabetes (2) | ESPE2014

‘My Diabetes’ Application for Android Devices as a Diabetes Management Tool

Ballester Maria Jose , Santillana Luis Alberto , Varvanov Rossen , Buch-Gasz Katarzyna , Gasz Adam , Sanchez Maria Jose , Lopez Carmen Maria , Martin Elena , Palomo Enrique

Introduction: A fundamental element in the successful diabetes management is the education of patients. Modern technology opens new horizons and provides new tools in empowering patients in their learning process.Objectives: Presentation, evaluation and critical medical review of ‘My Diabetes’ application whose Spanish version has been studied, reviewed and analysed in detail by our endocrinology unit and D-parents. Provide insight into its pot...

hrp0082p2-d2-380 | Fat Metabolism & Obesity (1) | ESPE2014

A New Case of Proopiomelanocortin Deficiency

Fuentes-Bolanos Noemi Auxiliadora , Madueno Francisco Jose Tinahones , Gonzalez Luis Castano , Gea Isabel Leiva , Ollero Maria Jose Martinez-Aedo , Lopez-Siguero Juan Pedro

Introduction: The proopiomelanocortin is a polypeptide of many biologically active peptides involved in many key functions which have not yet been clarified. The mutation in the gene encoding this polypeptide is associated with a clinical trials characterized by early-onset obesity, terciary adrenal insufficiency, and alteration of pigmentation. Eight cases with known genetic mutation have been published.Case report: Newborn male 27 days old from North A...